McCaffrey says Resverlogix has entered into the most exciting field in biotech and life sciences research right now, which is epigenetics.
He says that if genetics is the hardware of the human body, epigenetics is the software. Epigenetics is gaining attention of late, in part for its perceived potential to treat cances at the genetic level.
The Resverlogix CEO says the main catalysts for the company will be in licensing and partnering in epigenetics around oncology and autoimmune diseases. McCaffrey also points out that Phase 2B Assure Data, which in being conducted in eight different countries around the world, will be released in midway through 2013. He says that trial should prove, once and for all, that the treatment is removing atherosclerotic plaque.
Here’s the full video:
Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]
Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]
Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]
A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]
Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]
The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]